A Minority of Patients With High-Risk Polycythemia Vera Receive Cytoreductive Medication

Despite European LeukemiaNet and National Comprehensive Cancer Network guideline recommendations that patients with high-risk polycythemia vera (PV) should receive cytoreductive therapy along with phlebotomy and low-dose aspirin, a retrospective study found that only 42% of patients with high-risk PV received the recommended cytoreductive therapy.

 American Journal of Managed Care

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.